A Catenane Assembled through a Single Charge-Assisted Halogen Bond**
Lydia C. Gilday, Thomas Lang, Antonio Caballero, Paulo J. Costa, Vítor Félix, and Paul D. Beer*

anie_201300464_sm_misellaneous_information.pdf
# SUPPORTING INFORMATION

## TABLE OF CONTENTS

| Part I: Experimental Procedures | S2 |
|---------------------------------|----|
| General Notes                  | S2 |
| Synthesis                      | S2 |
| Pyridine macrocycle 1           | S2 |
| Halotriazolium thread components 2·BF₄, 3·BF₄ | S8 |
| Halopyridinium thread components 4·BF₄, 5·BF₄, 6·BF₄ | S15 |
| Catenane 7·BF₄                 | S22 |
| Part II: Spectral Characterisation of Catenane 7·BF₄ | S23 |
| High resolution MS of catenane 7·BF₄ | S23 |
| ¹³C NMR spectrum of catenane 7·BF₄ | S23 |
| 2D ¹H–¹H ROESY spectrum of catenane 7·BF₄ | S24 |
| Part III: Titration Protocols   | S24 |
| Part IV: Molecular modelling    | S25 |
| Part V: References             | S33 |
Part I: Experimental Procedures.

General Notes.

Commercially available solvents and chemicals were used without further purification unless stated. Where anhydrous solvents were used, they were degassed with nitrogen, dried by passing through a MBraun MPSP-800 column and then used immediately. Deionised water was used in all cases. Copper iodide, Tris[(1-Benzyl-1H-1,2,3-Triazol-4-yl)methyl]Amine (TBTA) and Grubbs’ 2nd generation catalyst were stored in a desiccator. NMR spectra were recorded on Varian Mercury 300, Varian Unity Plus 500 and Bruker AVII 500 (with $^{13}$C Cryoprobe) spectrometers. Mass spectra were carried out on Micromass LCT and Bruker microTOF spectrometers.

Syntheses.

Compounds 13$^1$, 14$^2$, 22$^3$, 26$^4$, 27$^5$, 28$^6$, and 29$^7$ were prepared following literature procedures.

Scheme 1: Synthesis of pyridine macrocycle 1. Reactions conditions: a) bromoethanol, K$_2$CO$_3$, DMF, 100 °C, 32%; b) NaH, THF, 45%; c) HCl, MeOH, 78%; d) Cs$_2$CO$_3$, DMF, 60 °C, 20%.
4-((tetrahydro-2H-pyran-2-yl)oxy)phenol 9:

![Chemical structure]

Hydroquinone (10.0 g, 91 mmol) and pyridinium *para*-toluenesulfonate (2.25 g, 9.1 mmol) were dissolved in degassed acetone (500 mL). A solution of 3,4-dihydro-2H-pyran (8.5 mL, 93 mmol) in degassed acetone (250 mL) was added dropwise and the reaction mixture stirred at r.t. for 6 days under N₂. The solvent was removed *in vacuo* and the crude brown oil was purified by column chromatography (Al₂O₃, EtOAc:cyclohexane 1:9 to 4:6) to yield the desired product 9 as a light yellow oil (5.22 g, 27 mmol, 29%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 6.93 (d, 2H, Ar, $^3J = 8.9$ Hz, hydroquinone-ArH), 6.72 (d, 2H, $^3J = 8.9$ Hz, hydroquinone-ArH), 5.28 (t, 1H, $^3J = 3.4$ Hz, OCH), 4.98 (s, 1H, OH), 3.95 (m, 1H, OCH₂), 3.60 (m, 1H, OCH₂), 1.82–1.87 (2H, m, CH₂), 1.57–1.72 (m, 4H, CH₂);

ESMS m/z: 193.1 ([M−H]⁻, C₁₁H₁₄O₃ requires 193.1).

2-(4-((tetrahydro-2H-pyran-2-yl)oxy)phenoxy)ethanol 10:

![Chemical structure]

Compound 9 (5.22 g, 27 mmol) and K₂CO₃ (7.4 g, 54 mmol) were dissolved in anhydrous DMF (250 mL). A solution of bromoethanol (3.8 mL, 54 mmol) in anhydrous DMF (50 mL) was added dropwise. The reaction mixture was then heated at 100 °C for 24 hr under N₂. After cooling to r.t., the reaction mixture was filtered, and the solvent removed *in vacuo*. The residue was then redissolved in hot CHCl₃ (75 mL), filtered and solvent removed *in vacuo*.
The crude brown oil was purified by column chromatography (Al₂O₃, EtOAc:cyclohexane 1:4 to 1:0) to yield the desired product 10 as a light yellow oil (2.07 g, 8.7 mmol, 32%).

¹H NMR (CDCl₃, 300 MHz) δ (ppm): 6.99 (d, 2H, ³J = 9.1 Hz, hydroquinone-Η), 6.84 (d, 2H, ³J = 9.1 Hz, hydroquinone-Η), 5.30 (t, ³J = 3.4 Hz, 1H, OCH), 4.03 (m, 2H, OCH₂), 3.93 (m, 3H, OCH₂), 3.59 (m, 1H, OCH₂), 1.82–1.87 (m, 2H, CH₂), 1.56–1.72 (m, 4H, CH₂); ¹³C NMR (CDCl₃, 75.5 MHz) δ (ppm): 153.6, 151.6, 117.9, 115.5, 97.4, 69.9, 62.2, 61.7, 30.6, 25.4, 19.0; ESMS m/z: 261.1 ([M+Na]+, C₁₃H₁₈NaO requires 261.1).

THP-protected pyridine macrocycle precursor 11:

NaH (60% in oil, 348 mg, 8.7 mmol) was suspended anhydrous THF (25 mL) and cooled to 0 °C. A solution of compound 10 (2.07 g, 8.7 mmol) in anhydrous THF (25 mL) was added dropwise and the reaction mixture was stirred at 0 °C, under N₂ for 1 hr. A solution of 2,6-bis(chloromethyl)pyridine (695 mg, 3.9 mmol) in anhydrous THF (25 mL) was added dropwise at 0 °C and the reaction mixture was heated at reflux under N₂ for 5 days. After cooling to r.t., the solvent was removed in vacuo, the residue was redissolved in CH₂Cl₂ (75 mL) and washed with H₂O (2 x 40 mL) and brine (3 x 40 mL), dried over anhydrous MgSO₄, filtered and the solvent removed in vacuo. The crude residue was purified by column chromatography (Al₂O₃, EtOAc:cyclohexane 0:1 to 1:0) to yield the desired product 11 as a colourless oil (1.01 g, 1.8 mmol, 45%).

¹H NMR (CDCl₃, 300 MHz) δ (ppm): 7.70 (t, ³J = 7.7 Hz, 1H, pyridine-Η⁴), 7.39 (d, ³J = 7.7 Hz, 2H, pyridine-Η² & Η⁴), 6.98 (d, ³J = 9.2 Hz, 4H, hydroquinone-Η), 6.85 (d,
$^{3}J = 9.2$ Hz, 4H, hydroquinone-H), 5.29 (t, $^{3}J = 3.3$ Hz, 2H, OCH), 4.73 (s, 4H, OCH$_2$), 4.13 (m, 4H, OCH$_2$), 3.90 (m, 6H, OCH$_2$), 3.58 (m, 2H, OCH$_2$), 1.81–1.85 (m, 4H, CH$_2$), 1.58–1.70 (m, 8H, CH$_2$); $^{13}$C NMR (CDCl$_3$, 75.5 MHz) $\delta$ (ppm): 157.9, 153.8, 151.5, 137.5, 120.2, 117.9, 115.6, 97.4, 74.3, 69.6, 68.1, 62.2, 30.6, 25.4, 19.1; ESMS m/z: 580.2897 ([M+H]$^+$, C$_{33}$H$_{42}$NO$_8$ requires 580.2905).

**Pyridine macrocycle precursor 12:**

![Pyridine macrocycle](image)

Compound 11 (2.01 g, 3.5 mmol) was dissolved in MeOH (200 mL), 600 µL of conc. HCl$_{\text{(aq)}}$ was added and the reaction mixture stirred at r.t. for 6 hr. The solution was neutralized with NaHCO$_3$(s) and solvent was removed *in vacuo*. The solid was washed with Et$_2$O (10 x 20 mL) to yield the desired product as a light yellow oil (1.19 g, 2.9 mmol, 78%).

$^1$H NMR (CDCl$_3$, 300 MHz) $\delta$ (ppm): 7.73 (t, 1H, $^{3}J = 7.8$ Hz, pyridine-H$^3$), 7.41 (d, $^{3}J = 7.8$ Hz, 2H, pyridine-H$^4$ & H$^5$), 6.73 (s, 8H, hydquinone-H), 5.86 (br, 2H, OH), 4.73 (s, 4H, OCH$_2$), 4.05 (m, 4H, OCH$_2$), 3.87 (m, 4H, OCH$_2$); $^{13}$C NMR (CDCl$_3$, 75.5 MHz) $\delta$ (ppm): 157.7, 152.8, 150.2, 145.5, 120.8, 116.2, 115.9, 73.8, 69.7, 68.1; ESMS m/z: 412.1742 ([M+H]$^+$, C$_{23}$H$_{26}$NO$_6$ requires 412.1755).
Pyridine macrocycle 1:

Cs₂CO₃ (1.66 g, 5.1 mmol) was suspended in anhydrous DMF (330 mL) and heated at 60 °C under N₂. Solutions of compound 12 (950 mg, 2.3 mmol) in anhydrous DMF (20 mL) and tetraethylene glycol bis-tosylate 13 (1.16 g, 2.3 mmol) in anhydrous DMF (20 mL) were added dropwise over a period of 20 hr. The reaction mixture was heated at 60 °C under N₂ for an additional 24 hr. After cooling to r.t., the reaction mixture was filtered and the solvent removed in vacuo. The residue was redissolved in hot CHCl₃ (40 mL), filtered and the solvent removed in vacuo. The crude brown oil was purified by column chromatography (SiO₂, EtOAc:cyclohexane 1:0 to 0:1) to yield the desired product 1 as a white solid (260 mg, 0.46 mmol, 20%).

¹H NMR (CDCl₃, 300 MHz) δ (ppm): 7.60 (t, ³J = 7.6 Hz, 1H, pyridine-H⁴) 7.27 (d, ³J = 7.6 Hz, 2H, pyridine-H³&H⁵), 6.76 (s, 8H, hydroquinone-H), 4.70 (s, 4H, OCH₂), 4.06 (m, 4H, OCH₂), 4.00 (m, 4H, OCH₂), 3.86 (m, 4H, OCH₂), 3.79 (m, 4H, OCH₂), 3.67 (m, 8H, OCH₂); ¹³C NMR (CDCl₃, 75.5 MHz) δ (ppm): 157.8, 153.2, 153.0, 137.3, 120.8, 115.9, 115.7, 74.2, 70.9, 70.9(sic), 69.9, 69.4, 68.3, 68.2; ESMS m/z: 570.2699 ([M+H]^+, C₃₁H₄₀NO₉ requires 570.2698).
**Scheme 2**: Synthesis of halotriazolium threads $2\cdot$BF$_4$ and $3\cdot$BF$_4$. Reactions conditions: a) K$_2$CO$_3$, ethyl-1,2-bis(4-methylbenzenesulfonate), MeCN, 45%; b) NaN$_3$, DMF, 85 °C, 98%; c) but-3-yn-1-ol, PPh$_3$, DEAD, THF, 45%; d) NBS or NIS, AgNO$_3$, acetone, 98%; e) 20: CuBr, Cu(AcO)$_2$, THF, 38%; 21: CuI, TBTA, 71%; f) Me$_3$OBF$_4$, CH$_2$Cl$_2$, $2\cdot$BF$_4$: 87%, $3\cdot$BF$_4$: 85%.

2-(4-(2-(allyloxy)ethoxy)phenoxy)ethyl-4-methylbenzenesulfonate, 15.

Compound 4-(2-(allyloxy)ethoxy)phenol 14 (0.5 g, 2.3 mmol) and K$_2$CO$_3$ (1.77 g, 12.8 mmol) were stirred for 20 min in MeCN (150 mL) and then ethyl-1,2-bis(4-methylbenzenesulfonate) (0.95 g, 2.6 mmol) was added and the reaction mixture heated to reflux under N$_2$ for 16 hr. After cooling to r.t. excess base was removed by filtration, the solvent removed in vacuo and then Et$_2$O was added to the crude residue precipitating the undesirable compounds. After filtering, the Et$_2$O was removed in vacuo giving the desired compound 15 as golden oil (0.41 g, 1.04 mmol, 45%).

$^1$H NMR (300 MHz, CDCl$_3$) δ (ppm): 7.80 (d, $^3J = 6$ Hz, 2H, ArH), 7.34 (d, $^3J = 6$ Hz, 2H, ArH), 6.81 (d, $^3J = 6$ Hz, 2H, hydroquinone-H), 6.70 (d, $^3J = 6$ Hz, 2H, hydroquinone-H), 5.87–5.98 (1H, m), 5.18–5.34 (m, 2H, CH$_2$), 4.31–4.34 (m, 2H, CH$_2$), 4.05–4.10 (6H, m),
3.75–3.78 (m, 2H, CH₂) 2.44 (s, 3H, CH₃); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 153.5, 152.3, 134.6, 132.9, 129.8, 128.0, 117.4, 115.7, 115.6, 73.4, 68.6, 68.3, 68.0, 66.2, 21.7; ESMS m/z: 393.1 ([M+H]^+, C₂₀H₂₄O₆S requires 393.1).

**1-(2-(allyloxy)ethoxy)-4-(2-azidoethoxy)benzene, 16.**

![Chemical structure](attachment:structure.png)

Compound 15 (0.41 g, 1.04 mmol) and NaN₃ (0.20 g, 3.07 mmol) in anhydrous DMF (20 mL) was stirred for 16 hr at 85 °C. The reaction was allowed to cool to r.t., poured into water (200 ml) at 0 °C and stirred for 10 min. The organic compounds were extracted with Et₂O (4 x 200 mL) and the combined organic extracts were dried over anhydrous MgSO₄, filtered, and the solvent removed in vacuo to give compound 16 as a golden oil (0.26 g, 0.99 mmol, 98%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 6.84 (d, ³J = 6.0 Hz, 2H, hydroquinone-H), 6.81 (d, ³J = 6 Hz, 2H, hydroquinone-ArH), 5.87–5.94 (m, 1H, C=CH), 5.15–5.29 (m, 2H, C=CH₂), 4.31–4.34 (m, 2H, CH₂), 4.02–4.05 (m, 6H, CH₂), 3.73 (t, ³J = 3 Hz, 2H, CH₂), 3.50 (t, ³J = 3 Hz, 2H, CH₂); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 152.5, 134.6, 117.4, 115.7, 115.6, 72.4, 68.6, 68.1, 67.6, 55.2; ESMS m/z: 264.13 ([M+H]^+, C₁₃H₁₈N₃O₃ requires 264.13).

**1-(2-(allyloxy)ethoxy)-4-(but-3-ynyloxy)benzene, 17.**

![Chemical structure](attachment:structure.png)

To a solution of 4-(2-(allyloxy)ethoxy)phenol 14 (1.09 g, 5.6 mmol), but-3-yn-1-ol (0.43 mL, 5.6 mmol) and PPh₃ (1.47 g, 56 mmol) in anhydrous THF (150 mL) at 0 °C was added dropwise 0.92 ml (5.6 mmol) of Diethyl azodicarboxylate (0.92 mL, 5.6 mmol). The resulting
solution was stirred at r.t. under N₂ for 16 hr. The solvent was removed in vacuo and the resultant residue was purified by column chromatography (SiO₂, 8:0.5 CH₂Cl₂:EtOH) to give the product 17 as a white solid (0.63 g, 2.56 mmol, 45%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 6.85 (s, 4H, hydroquinone-H), 5.87–6.00 (m, 1H, C=CH), 5.18–5.34 (m, 2H, C=CH₂), 5.06–5.10 (m, 4H, C₆H₂), 3.73 (t, 3J = 3 Hz, 2H, CH₂), 3.77 (t, 3J = 3 Hz, 2H, CH₂), 2.64 (2H, td, J = 9 Hz, J = 3Hz, CH₂), 2.03 (t, 4J = 3 Hz, 1H alkyl-CH); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 153.3, 152.6, 134.6, 117.4, 115.7, 115.6, 80.6, 72.4, 69.8, 68.6, 68.1, 66.7, 19.6; ESMS m/z: 247.13 ([M+H]⁺, C₁₅H₁₉O₃ requires 247.13).

1-(2-(allyloxy)ethoxy)-4-(4-bromobut-3-ynloxy)benzene 18

To a solution of compound 17 (0.26 g, 1 mmol) in acetone (20 mL) were added N-bromosuccinimide (0.23 g, 1.3 mmol) and AgNO₃ (18 mg, 0.1 mmol). The reaction mixture was left to stir for 16 hr at r.t. in the dark under N₂, after which a yellow suspension formed. All volatile components were removed in vacuo to give a yellow oil, which was purified by column chromatography (SiO₂, 98:2 CH₂Cl₂:MeOH) to give compound 17 as a white solid (0.32 g, 0.98 mmol, 98%);

¹H NMR (300 MHz, CDCl₃) δ (ppm): 6.87 (d, 3J = 6 Hz, 2H, hydroquinone-H), 6.83 (d, 3J = 6 Hz, 2H, hydroquinone-H), 5.88–6.01 (m, 1H, C=CH), 5.19–5.34 (m, 2H, C=CH₂), 4.06–4.10 (m, 6H, CH₂), 3.78 (t, 3J = 3 Hz, 2H), 3.66 (t, 3J = 6 Hz, 2H, CH₂); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 153.3, 152.6, 134.6, 117.4, 115.7, 115.6, 72.4, 68.6, 68.0, 66.4, 39.9, 20.8; ESMS m/z: 325.04 ([M+H]⁺, C₁₅H₁₈BrO₃ requires 325.04).
1-(2-(allyloxy)ethoxy)-4-(4-iodobut-3-nyloxy)benzene, 19.

\[
\begin{align*}
\text{To a solution of compound 17 (0.28 g, 1.1 mmol) in acetone (20 mL) were added } N-
\text{iodosuccinimide (0.31 g, 1.3 mmol) and AgNO}_3 (23 \text{ mg, 0.13 mmol). The reaction mixture }
\text{was left to stir for 16 hr at r.t. in the dark under N}_2(g), \text{ after which a yellow suspension }
\text{formed. All volatile components were removed } \text{in vacuo} \text{ to give a yellow oil, which was }
\text{purified by column chromatography (SiO}_2, 98:2 \text{ CH}_2\text{Cl}_2:\text{MeOH} ) \text{ to give compound 19 as a }
\text{white solid (0.4 g, 1.07 mmol, 98\%.}}
\end{align*}
\]

\[ \text{\textsuperscript{1}H NMR (300 MHz, CDCl}_3 \] \( \delta \) (ppm): 6.86 (d, \( \text{\textsuperscript{3}J = 6 Hz} \), 2H, hydroquinone-H), 6.81 (d, \( \text{\textsuperscript{3}J = 6 Hz} \), 2H, hydroquinone-H), 5.87–6.00 (m, 1H, C=CH), 5.21–5.33 (m, 2H, C=CH\text{)}, 4.06–4.10 (m, 6H, CH\text{\text{2}}), 3.77 (t, \( \text{\textsuperscript{3}J = 3 Hz} \), 2H, CH\text{\text{2}}), 2.80 (t, \( \text{\textsuperscript{3}J = 6 Hz} \), 2H, CH\text{\text{2}}); \text{\textsuperscript{13}C NMR } \\
\text{(75.5 MHz, CD}_2\text{Cl}_2 \] \( \delta \) (ppm): 153.3, 152.6, 134.6, 117.4, 115.7, 115.6, 110.0, 90.49, 72.35, 68.6, 68.1, 66.6, 21.8; ESMS \( m/\zeta \): 373.02 ([M+H]\textsuperscript{+}\text{), C}_{15}\text{H}_{18}\text{IO}_3\text{requires 373.02).}
\]

1,4-bis(2-(4-(2-(allyloxy)ethoxy)phenoxy)ethyl)-5-bromo-1H-1,2,3-triazole, 20.

\[
\begin{align*}
\text{CuBr (0.14 g 0.98 mmol) and Cu(AcO)}_2 (0.18 g, 0.98 \text{ mmol) were stirred in anhydrous THF}
\text{ (10 mL) for 20 min. This catalyst solution was added to a solution of bromoalkyne 18 (0.32 g, 0.98}
\text{ mmol) and azide 16 (0.26 g, 0.98 mmol) and the reaction was stirred in the dark for 16 hr at 50 °C before }
\text{being quenched with 10\% NH}_4\text{OH(aq) solution (2 mL). Volatile components were removed } \text{in vacuo, H}_2\text{O (20 mL) was added and the aqueous phase was}
\end{align*}
\]
extracted with CH$_2$Cl$_2$ (3 x 20 mL) The combined organic phases were dried over anhydrous MgSO$_4$, filtered and concentrated to dryness on a rotary evaporator to give a pale yellow solid. The crude product was purified by column chromatography (SiO$_2$, 95:5 CH$_2$Cl$_2$:MeOH) to give compound 20 as a white solid (0.22 g, 25.9 mmol, 38%).

$^1$H NMR (300 MHz, CDCl$_3$) δ (ppm): 6.74–6.86 (m, 8H, hydroquinone-$H$), 5.87–5.98 (m, 2H, C=CH), 5.18–5.33 (m, 4H, C=CH$_2$), 4.69 (t, $^3$J = 6 Hz, 2H, CH$_2$), 4.35 (t, $^3$J = 6 Hz, 2H, CH$_2$), 4.21 (t, $^3$J = 6 Hz, 2H, CH$_2$), 4.09–4.04 (m, 8H, CH$_2$), 3.76 (t, $^3$J = 3 Hz, 4H, CH$_2$), 3.12 (t, $^3$J = 6 Hz, 2H, CH$_2$); $^{13}$C NMR (75.5 MHz, CDCl$_3$) δ (ppm): 153.6, 153.1, 153.0, 152.14, 143.24, 134.5, 117.33, 115.6, 115.5, 72.4, 68.6, 68.1, 66.7, 66.6, 48.4, 25.7; ESMS m/z: 588.16 ([M+H]$^+$, C$_{28}$H$_{34}$BrN$_3$O$_6$ requires 588.16).

1,4-bis(2-(4-(2-(allyloxy)ethoxy)phenoxy)ethyl)-5-iodo-1H-1,2,3-triazole, 21.

CuI (0.063 g 0.33 mmol) and TBTA (0.17 g, 0.33 mmol) were stirred in anhydrous THF (10 ml) for 20 min. The catalyst solution was added to a solution of iodoalkyne 19 (0.31 g, 0.83 mmol) and azide 16 (0.22 g, 0.83 mmol) and the reaction left to stir in the dark for 16 hr at r.t. before being quenched with 10% NH$_4$OH$_{(aq)}$ solution (2 mL). Volatile components were removed in vacuo. H$_2$O (20 mL) was added and the aqueous phase was extracted with CH$_2$Cl$_2$ (3 x 20 mL). The combined organic fractions were dried over anhydrous MgSO$_4$, filtered and concentrated to dryness on a rotary evaporator to give a pale yellow solid. The crude product was purified by column chromatography (SiO$_2$, 95:5 CH$_2$Cl$_2$:MeOH) to give yellow oil (0.150 g, 0.24 mmol, 71 %).
1H NMR (300 MHz, CDCl₃) δ (ppm): 6.76–6.76 (m, 8H, hydroquinone-H), 5.88–5.99 (m, 2H, C=CH), 5.20–5.34 (m, 4H, C=CH₂), 4.74 (t, 3J = 6 Hz, 2H, CH₂), 4.37 (t, 3J = 6 Hz, 2H, CH₂), 4.22 (t, 3J = 6 Hz, 2H, CH₂), 4.05–4.10 (m, 8H, C=CH₂), 3.78 (t, 3J = 3 Hz, 4H, C=CH₂), 3.15 (2H, t, 3J = 6 Hz); 13C NMR (75.5 MHz, CDCl₃) δ 153.7, 153.3, 153.0, 152.4, 143.2, 134.5, 117.4, 115.6, 115.5, 72.6, 68.9, 68.3, 66.7, 66.7, 48.5, 25.8; ESMS m/z: 636.15 ([M+H]+, C₂₈H₃₄IN₃O₆ requires 636.15).

1,4-bis(2-(4-(2-(allyloxy)ethoxy)phenoxy)ethyl)-5-bromo-1H-1,2,3-triazol-3-ium tetrafluoroborate, 2·BF₄⁻.

Bromotriazole 20 (0.22 g, 0.37 mmol) was dissolved in anhydrous CH₂Cl₂ (25 mL), Me₃OBF₄ (0.082 g, 0.55 mmol) was added, and the reaction mixture stirred at r.t. under N₂ for 48 hr. MeOH (2 mL) was added and all volatile components were removed in vacuo to give a yellow oil, which was purified by column chromatography (SiO₂, 98:2 CH₂Cl₂:MeOH) to give a yellow oil (0.22 g, 0.32 mmol, 87%).

1H NMR (300 MHz, CDCl₃) δ (ppm): 6.72–6.82 (m, 8H, hydroquinone-H), 5.87–5.98 (m, 2H, C=CH), 5.18–5.32 (m, 4H, C=CH₂), 4.90 (t, 3J = 6 Hz, 2H, CH₂), 4.46 (t, 3J = 6 Hz, 2H, CH₂), 4.37 (s, 3H, CH₃), 4.18 (t, 3J = 6 Hz, 2H, CH₂), 4.03–4.07 (m, 8H, CH₂), 4.05 (t, 3J = 3Hz, 4H, CH₂), 3.76 (t, 3J = 6 Hz, 2H, CH₂); 13C NMR (75.5 MHz, CD₂Cl₂) δ 153.4, 153.5, 151.9, 151.6, 146.1, 134.6, 117.4, 115.7, 115.6, 115.5, 115.3, 89.5, 71.9, 68.4, 65.5, 65.4, 58.7, 53.8, 39.1, 25.4; ESMS m/z: 602.19, ([M–BF₄]⁺, C₂₉H₃₇BrN₅O₆ requires 602.19).
1,4-bis(2-(4-(2-(allyloxy)ethoxy)phenoxy)ethyl)-5-iodo-1H-1,2,3-triazol-3-ium tetrafluoroborate, 3-BF₄.

Iodotriazole 21 (0.250 g, 0.39 mmol) was dissolved in anhydrous CH₂Cl₂ (25 mL), Me₃OBF₄ was added (0.145 g, 0.97 mmol) and the reaction mixture stirred at r.t., under N₂ for 48 hr. MeOH (2 mL) was added and all volatile components were removed in vacuo to give a yellow oil, which was purified by column chromatography (SiO₂, 98:2 CH₂Cl₂:MeOH) to give a yellow oil (0.24 g, 0.33 mmol, 85%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 6.67–6.77 (m, 8H, hydroquinone-H), 5.82–5.92 (m, 2H, C=CH), 5.13–5.29 (m, 4H, C=CH₂), 4.82 (t, ³J = 6 Hz, 2H, CH₂), 4.37 (t, ³J = 6 Hz, 2H, CH₂), 4.31 (s, 3H, CH₃), 4.11 (t, ³J = 6Hz, 2H, CH₂), 3.96–4.03 (m, 8H, CH₂), 3.70 (t, ³J = 3 Hz, 4H, CH₂), 3.30 (t, ³J = 6Hz, 2H, CH₂); ¹³C NMR (75.5 MHz, CD₂Cl₂) δ (ppm): 153.7, 153.6, 151.8, 151.6, 146.0, 134.5, 117.4, 115.7, 115.6, 115.5, 115.3, 89.9, 72.3, 68.5, 65.4, 65.2, 58.3, 53.8, 39.1, 25.4; ESMS m/z: 650.17 ([M–BF₄]⁺, C₂₉H₃₁N₅O₆ requires 650.17).
Scheme 3: Synthesis of halopyridinium threads $4\cdot\text{BF}_4$, $5\cdot\text{BF}_4$ and $6\cdot\text{BF}_4$. Reaction conditions: a) NaI, acetyl chloride, MeCN, 74%; b) NaBH$_4$, MeOH, 68%; c) imidazole, PPh$_3$, I$_2$, CH$_2$Cl$_2$, 32%; d) Na'BuO, MeCN, 81%; e) NaH, THF, 31: 82%, 32: 85%, 33: 56%; f) Me$_3$BF$_4$, CH$_2$Cl$_2$, $4\cdot\text{BF}_4$: 33%; $5\cdot\text{BF}_4$: 38%; $6\cdot\text{BF}_4$: 51%.

**Dimethyl 4-iodopyridine-2,6-dicarboxylate, 23.**

Compound 23 (2.00 g, 8.73 mmol) was dissolved in MeCN (100 mL), NaI (13.1 g, 87.3 mmol) was added and the reaction mixture was sonicated (bath sonicator) for 30 min. Acetyl chloride (1.86 mL, 26.2 mmol) was added and the reaction mixture sonicated for a further 45 min. CH$_2$Cl$_2$ (100 mL) and sat. Na$_2$CO$_3$(aq) (100 mL) were added, the organic phase was separated and the aqueous phase extracted with CH$_2$Cl$_2$ (3 x 100 mL). The combined organic phases were washed with sat. Na$_2$S$_2$O$_3$·5H$_2$O(aq) (1 x 200 mL), H$_2$O (1 x 200 mL), dried over anhydrous MgSO$_4$, filtered and the solvent removed *in vacuo* to give 24 as a white solid in 74% yield (2.06 g, 6.42 mmol).
\(^1\)H NMR (300 MHz, CDCl\(_3\)) \(\delta\) (ppm): 8.67 (s, 2H, pyridine-\(H^3\&H^5\)), 4.03 (s, 6H, CH\(_3\)); ESMS \(m/z\): 344.0 ([M+Na]\(^+\), C\(_9\)H\(_8\)INNaO\(_4\) requires 343.9).

(4-Iodopyridine-2,6-diyl)dimethanol, 24.

\[
\begin{array}{c}
\text{HO} \\
\text{N} \\
\text{OH} \\
\text{I} \\
\end{array}
\]

Compound 23 (750 mg, 2.34 mmol) was dissolved in MeOH (50 mL) and cooled to 0 °C. NaBH\(_4\) (266 mg, 7.02 mmol) was added and the reaction mixture heated at reflux for 16 hr. After cooling to r.t. acetone (20 mL) was added and the solvent removed \textit{in vacuo}. Sat. NaHCO\(_3\)(aq) (3.5 mL) was added and the suspension heated to boiling forming a yellow solution. H\(_2\)O (4.5 mL) was added and the resulting precipitate cooled at 4 °C for 16 hr. The mixture was filtered and the solid dried in air to give compound 24 as a white solid (419 mg, 1.58 mmol, 68%).

\(^1\)H NMR (300 MHz, acetone-d\(_6\)) \(\delta\) (ppm): 7.78 (s, 2H, pyridine-\(H^3\&H^5\)), 4.63 (s, 4H, CH\(_2\)), 4.53 (s, 2H, OH); ESMS \(m/z\): 266.0 ([M+H]\(^+\), C\(_7\)H\(_9\)INO\(_2\) requires 266.0).

4-iodo-2,6-bis(iodomethyl)pyridine, 25.

\[
\begin{array}{c}
\text{I} \\
\text{N} \\
\text{I} \\
\end{array}
\]

Compound 24 (300 mg, 1.13 mmol), imidazole (720 mg, 2.74 mmol) and PPh\(_3\) (633 mg, 9.30 mmol) were dissolved in anhydrous CH\(_2\)Cl\(_2\) (100 mL). A solution of I\(_2\) (723 mg, 2.85 mmol) in anhydrous CH\(_2\)Cl\(_2\) (100 mL) was added in portions and the reaction stirred at r.t. under N\(_2\) for 16 hr. The solvent was removed \textit{in vacuo} and the crude residue purified by column chromatography (SiO\(_2\), CH\(_2\)Cl\(_2\)) to give 30 as an orange solid (174 mg, 0.36 mmol, 32%).
**1H NMR (300 MHz, C₆D₆) δ (ppm): 6.83 (s, 2H, pyridine-H³&H⁵), 3.72 (s, 4H, CH₂). ESMS m/z: 485.7710 ([M+H]^+; C₇H₁₇I₃N requires 485.7707). This compound was used immediately without further characterisation.**

**2-(4-(2-(Allyloxy)ethoxy)phenoxy)ethanol, 30.**

[Chemical structure]

Compound 28 (1.80 g, 11.7 mmol), compound 29 (3.00 g, 11.7 mmol) and sodium tert-butoxide (1.27 g, 13.2 mmol) were dissolved in MeCN (150 mL) and heated at reflux for 48 hr under N₂. The mixture was cooled and filtered through Celite®. The solvent was removed in vacuo and the resulting residue was purified by column chromatography to give compound 32 as a cream coloured solid (2.26 g, 9.48 mmol, 81%).

**1H NMR (300 MHz, CDCl₃) δ (ppm): 6.83–6.90 (m, 4H, hydroquinone-H), 5.89–6.02 (m, 1H, C=CH), 5.19–5.35 (m, 2H, C=CH₂), 4.08–4.12 (m, 4H, CH₂), 4.03–4.06, (m, 2H, CH₂), 3.93–3.97 (m, 2H, CH₂), 3.79 (t, ³J = 5.0 Hz, 2H, CH₂), 2.02 (br s, 1H, OH); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 153.3, 152.9, 134.5, 117.4, 115.6, 115.4, 72.4, 69.8, 68.6, 68.0, 61.6; ESMS m/z: 261.1097 ([M+Na]^+; C₁₃H₁₈O₄ requires 261.1107).**

**2,6-bis((2-(4-(2-(allyloxy)ethoxy)phenoxy)ethoxy)methyl)pyridine, 31.**

[Chemical structure]

NaH (60% dispersion in mineral oil, 168 mg, 4.20 mmol) was suspended in anhydrous THF (50 mL), cooled to 0 °C and compound 30 (224 mg, 0.85 mmol) in anhydrous THF (10 mL) was added dropwise. After stirring at r.t. under N₂ for 30 min compound 27 was added. The reaction mixture was stirred at r.t. under N₂ for 2 weeks after which H₂O (100 mL) was added and the THF removed in vacuo. The aqueous mixture was extracted with CH₂Cl₂...
(3 x 100 mL), dried over anhydrous MgSO₄, filtered and the solvent removed in vacuo. The crude residue was purified by column chromatography (SiO₂, 9:1 CH₂Cl₂:acetone) to give 31 as a white solid (406 mg, 0.70 mmol, 82%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.70 (t, ³J = 8.1 Hz, 1H, pyridine-H⁴), 7.40 (d, ³J = 8.1 Hz, 2H, pyridine-H³ & H⁵), 6.86 (s, 8H, hydroquinone-H), 5.88–6.01 (m, 2H, C=C-H), 5.18–5.34 (m, 4H, C=C-H₂), 4.70 (s, 4H, C=CH₂), 4.15 (t, ³J = 4.5 Hz, 4H, CH₂), 3.90 (t, ³J = 4.8 Hz, 4H, CH₂), 3.77 (t, ³J = 5.0 Hz, 4H, CH₂); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 157.7, 153.0, 137.2, 134.5, 120.0, 117.2, 115.5, 74.0, 72.3, 69.4, 68.5, 67.9, 67.9 (sic), 30.2, 29.6. ESMS m/z: 580.2891 ([M+H]+, C₃₃H₄₂NO₈ requires 580.2905).

2,6-bis((2-(4-(2-(allyloxy)ethoxy)phenoxy)ethoxy)methyl)-4-bromopyridine, 32.

NaH (60% dispersion in mineral oil, 270 mg, 6.75 mmol) was suspended in anhydrous THF (50 mL) and cooled to 0 °C under N₂. Compound 30 (523 mg, 2.19 mmol) was dissolved in anhydrous THF (20 mL) and added dropwise to the first solution. The mixture was stirred for at r.t. under N₂ for 30 min. Compound 26 (301 mg, 0.88 mmol) was added and the reaction stirred at r.t. under N₂ for 6 days. H₂O (50 mL) was added, the volatiles removed in vacuo and the aqueous phase was extracted with CH₂Cl₂ (3 x 100 mL). The combined organic phases were dried over anhydrous MgSO₄, filtered and the solvent removed in vacuo. The crude residue was purified using column chromatography (SiO₂, 9:1 CHCl₃:acetone) to give 32 as a creamy solid (487 mg 0.73 mmol, 85%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.61 (s, 2H, pyridine-H³ & H⁵), 6.88 (s, 8H, hydroquinone-H), 5.89–6.02 (m, 2H, C=CH), 5.19–5.35 (m, 4H, C=CH₂), 4.70 (s, 4H, CH₂O), 4.15 (t, ³J = 4.5 Hz, 4H, CH₂), 4.08–4.12 (m, 8H, CH₂), 3.91 (t, ³J = 5.0 Hz, 4H,
2,6-bis(2-(4-(2-(allyloxy)ethoxy)phenoxy)ethoxy)methyl)-4-iodopyridine, 33.

NaH (107 mg, 2.68 mmol) was suspended in anhydrous THF (100 mL) and cooled to 0 °C. 30 (250 mg, 1.05 mmol) was added and stirred at r.t. under N₂ for 30 min. Compound 25 (174 mg, 0.36 mmol) was added and the reaction mixture stirred at r.t. under N₂ for 72 hr. H₂O (100 mL) was added and the THF removed in vacuo. The aqueous mixture was extracted with CH₂Cl₂ (3 x 100 mL) and the combined organic extracts dried over anhydrous MgSO₄, filtered and the solvent removed in vacuo. The crude residue was purified by column chromatography (SiO₂, 9:1 CH₂Cl₂:acetone) to give 33 as a pale yellow solid (144 mg, 0.20 mmol, 56%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 7.82 (s, 2H, pyridine- H³ & H⁵), 6.88 (s, 8H, hydroquinone-H), 5.89–6.02 (m, 2H, C=CH), 5.19–5.35 (m, 4H, C=CH₂), 4.68 (s, 4H, OCH₂)
4.15 (t, 3J = 4.7 Hz, 4H, CH₂), 4.08–4.11 (m, 8H, CH₂), 3.91 (t, 3J = 4.7 Hz, 4H, CH₂), 3.79 (t, 3J = 5.0 Hz, 4H, CH₂); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 152.7, 152.5, 146.5, 134.1, 128.7, 116.9, 115.15, 115.07, 103.1, 72.8, 71.9, 69.3, 68.2, 67.6, 67.4; ESMS m/z: 728.1699 ([M+Na]+, C₃₃H₄₀BrNaNO₈ requires 728.1691).
Pyridinium tetrafluoroborate thread, 4-BF₄.

Compound 31 (100 mg, 0.17 mmol) was dissolved in anhydrous CH₂Cl₂ (50 mL) and Me₃OBF₄ (30.6 mg, 0.21 mmol) was added. The reaction mixture was stirred at r.t. under N₂ for 72 hr after which, MeOH (1 mL) was added and the solvent removed in vacuo. The crude residue was purified by column chromatography (SiO₂, 95:5 CH₂Cl₂:MeOH) to give 4-BF₄ as a pale yellow oil (33.2 mg, 55.8 μmol, 33%).

¹H NMR (300 MHz, CDCl₃) δ (ppm): 8.29 (t, ³J = 8.0 Hz, 1H, pyridinium-⁴H), 8.03 (d, ³J = 8.0 Hz, 2H, pyridinium-⁵H&₆H), 6.80-6.87 (m, 8H, hydroquinone-H), 5.88–6.01 (m, 2H, C=CH), 5.19–5.35 (m, 4H, C=CH₂), 5.00 (s, 4H, CH₂), 4.06–4.14 (m, 15H, CH₂& NC₃H₇), 4.02–3.99 (m, 4H, CH₂), 3.78 (t, ³J = 4.7 Hz, 4H, CH₂); ¹³C NMR (75.5 MHz, CDCl₃) δ (ppm): 155.5, 153.3, 152.6, 144.7, 134.5, 126.1, 117.3, 115.6, 115.5, 72.3, 70.5, 68.6, 68.0, 67.6, 39.2. ¹⁹F NMR (282.5 MHz, CDCl₃) δ (ppm): −153.1−153.0 (m, BF₄). ESMS m/z: 594.3047 ([M−BF₄]+, C₃₄H₄₄NO₈ requires 594.3061).

4-Bromopyridinium tetrafluoroborate thread, 5-BF₄.

Compound 32 (50 mg, 0.076 mmol) was dissolved in anhydrous CH₂Cl₂ (30 mL). Me₃OBF₄ (15 mg, 0.1 mmol) was added and the reaction stirred at r.t. under N₂ for 4 days. MeOH (1 mL) was added and the solvent removed in vacuo. The crude residue was purified using preparative thin layer chromatography (SiO₂, 9:1 CH₂Cl₂:MeOH) to yield 5-BF₄ as a pale orange oil (22 mg, 0.030 mmol, 38%).
$^1$H NMR (300 MHz, CDCl$_3$) δ (ppm): 8.22 (s, 2H, pyridinium-$H^3$&$H^5$), 6.85 (s, 8H, hydroquinone-$H$), 5.88–6.01 (m, 2H, C=CH), 5.19–5.34 (m, 4H, C=CH$_2$), 4.94 (s, 4H, OCH$_2$), 4.00–4.14 (m, 16H, CH$_2$), 3.97 (s, 3H, CH$_3$), 3.77 (t, 4H, $^3$J = 5.0 Hz, CH$_2$); $^{13}$C NMR (75.5 MHz, CDCl$_3$) δ (ppm): 153.3, 152.6, 143.6, 134.5, 128.7, 117.3, 115.6, 115.4, 72.3, 70.7, 68.6, 68.0, 67.9, 38.8; $^{19}$F NMR (282.5 MHz, CDCl$_3$) δ (ppm): –153.1––153.2 (m, BF$_4$). ESMS m/z: 672.2163 ([M–BF$_4$]$^+$, C$_{34}$H$_{43}$BrNO$_8$ requires 672.2167).

4-Iodopyridinium tetrafluoroborate thread, 6·BF$_4$.

Compound 33 (28 mg, 37.9 μmol) was dissolved in anhydrous CH$_2$Cl$_2$ (10 mL). Me$_3$OBF$_4$ (7.60 mg, 51.4 μmol) was added and the reaction mixture was stirred at r.t. under N$_2$ for 48 hr. MeOH (1 mL) was added and the solvent removed in vacuo. The crude residue was purified by preparative thin layer column chromatography (SiO$_2$, 95:5 CH$_2$Cl$_2$:CH$_3$OH) to give 6·BF$_4$ as a pale orange oily solid (15.5 mg, 19.4 μmol, 51%).

$^1$H NMR (300 MHz, CDCl$_3$) δ (ppm): 8.41 (2H, s, pyridinium-$H^3$&$H^5$), 6.86 (s, 8H, hydroquinone-$H$), 5.88–6.01 (m, 2H, C=CH), 5.20–5.35 (m, 4H, C=CH$_2$), 4.13–4.15 (m, 4H, CH$_2$), 4.07–4.10 (m, 8H, CH$_2$), 4.01–4.04 (m, 4H, CH$_2$), 3.98 (s, 3H, CH$_3$), 3.78 (t, $^3$J = 4.9 Hz, 4H, CH$_2$). $^{13}$C NMR (75.5 MHz, CDCl$_3$) δ (ppm): 154.8, 153.3, 152.7, 135.0, 134.5, 117.4, 115.7, 115.5, 72.3, 70.7, 68.6, 68.0, 67.7, 67.5, 38.9; $^{19}$F NMR (282.5 MHz, CDCl$_3$) δ (ppm): –153.1––153.0 (m, BF$_4$). ESMS m/z: 720.2018 ([M–BF$_4$]$^+$, C$_{34}$H$_{43}$INO$_8$ requires 720.2028).
Catenane 7-BF$_4$

Compound 6-BF$_4$ (75.6 mg, 97.0 μmol) and pyridine macrocycle 1 (50 mg, 88.0 μmol) were dissolved in anhydrous CH$_2$Cl$_2$ (3 mL). Grubbs’ II catalyst (10% by wt, 7.6 mg) was added and the reaction mixture stirred at r.t. under N$_2$ for 4 days. A further portion of Grubbs’ II catalyst (3.5 mg) was added and the reaction mixture stirred for a further 24 hr. The solvent was removed in vacuo and the crude residue purified by successive preparative thin layer chromatography plates (SiO$_2$, 9:1 CH$_2$Cl$_2$:CH$_3$OH, 9:1 EtOAc:CH$_3$CN and 1:1 CH$_2$Cl$_2$:CH$_3$CN) to give 7-BF$_4$ as a white solid (8.56 mg, 6.35 μmol, 6.5%).

$^1$H NMR (300 MHz, CDCl$_3$) δ (ppm): 7.79 (t, $^3$J = 7.6 Hz, 1H, pyridine-H$_4$), 7.38–7.40 (m, 4H, pyridine-H$_3$&H$_5$, pyridinium-H$_3$&H$_5$), 6.84–6.87 (m, 4H, hydroquinone-H), 6.77–6.80 (m, 4H, hydroquinone-H), 6.43–6.46 (m, 4H, hydroquinone-H), 6.31–6.34 (m, 4H, hydroquinone-H), 5.79 (s, 2H, alkene-CH), 4.89 (s, 4H, +N(CH$_3$)CCH$_2$), 4.19–4.22 (m, 4H, CH$_2$), 4.11–4.12 (m, 4H, CH$_2$), 3.97–4.04 (m, 15H, C$_6$H$_2$), 3.92–3.95 (s, 4H, C$_6$H$_2$), 3.72–3.75 (m, 4H, CH$_2$), 3.78–3.80 (m, 12H, CH$_2$), 3.46 (br s, 4H, CH$_2$), $^{13}$C NMR (125.8 MHz, CDCl$_3$) δ (ppm): 153.1, 152.80, 152.75, 152.7, 152.3, 154.4, 128.9, 115.6, 115.4, 115.3, 115.0, 114.8, 114.6, 69.6, 69.6, 69.0, 68.2, 68.1, 67.6, 67.1, 66.7, 29.7, 14.1; $^{19}$F NMR (282.5 MHz, acetone-d$_6$) δ (ppm): −151.83—−151.78 (m, BF$_4$); ESMS $m/z$: 1261.4345 ([M–BF$_4$]$^+$, C$_{63}$H$_{76}$In$_2$O$_{17}$ requires 1261.4340).
Part II: Spectral Characterisation of Catenane 7-BF₄.

Figure S1: High resolution mass spectrum of catenane 7-BF₄

Figure S2: ¹³C NMR spectrum of catenane 7-BF₄ (125.8 MHz, CDCl₃, 298 K).
Part III: Titration Protocols.

$^1$H NMR spectra were recorded on a Varian Unity Plus 500 spectrometer. Typically, a solution of guest was added to a solution of the host at 293 K. The chemical shift of the hydroquinone protons signal of the host was monitored for seventeen titration points (for 0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 4.0, 5.0, 7.0 and 10.0 equivalents of added guest). The resulting data were analysed using the WinEQNMR2 computer program in experiments where association of guest and host was fast on the NMR timescale. Pseudorotaxane titration experiments were carried out using the tetrafluoroborate salt of the threading component guest species (2-BF$_4$, 3-BF$_4$, 4-BF$_4$, 5-BF$_4$, 6-BF$_4$), titrated into the host species pyridine macrocycle 1. A 0.139 mol dm$^{-3}$ solution of thread was added to 0.5 mL of a 0.00191 mol dm$^{-3}$ solution of macrocycle. The volumes of thread solution added were 10 x 4 μL, 2 x 10 μL, 2 x 20 μL, 1 x 40 μL, and 1 x 60 μL.

The values of the observed chemical shift and the guest concentration were entered into winEQNMR2 for every titration point, and estimates for the association constant, limiting
chemical shifts and binding stoichiometry made. The parameters were refined using non-linear least squares analysis to obtain the best fit between observed and calculated chemical shifts; the program plots the observed shift versus the guest concentration, revealing the accuracy of the experimental data and the suitability of the model used. The input parameters were varied until the best-fit values of the stability constants, together with their errors, converged.

**Part IV: Molecular Modelling.**

**Computational Details.**

**DFT calculations and halogen bond parameterization for Molecular Dynamics simulations.** The ability of [2]catenane 7 to form C-I···N halogen bonding interactions, was investigated by classical Molecular Dynamics (MD) simulations, using a similar procedure reported by us in references[^8] and [^9]. The specific force field parameters used to describe these interactions were developed as follows. DFT calculations were performed with Gaussian 09[^10] using the hybrid functional B3LYP[^11] on systems A1, and B1 (see Figure S4), models for the I···N interaction in 7+. System B1 contains two meta-methoxy substituents as mimetic groups of the ether linkages of the two interlocked macrocycles on the [2]catenane assembly.

![Figure S4: Optimised B3LYP gas phase structures of A1 and B1 models used in the parameterization of C-I···N charged assisted interactions.](image-url)
For C, O, H, and N the standard 6-311+G** basis set was used while I was described by the aug-cc-pVDZ-PP basis set and pseudo potential taken from the EMSL Basis Set Exchange website.\textsuperscript{[12]} The geometries were optimized in the gas phase and, for the larger model B1, solvent effects (CHCl\textsubscript{3}) were also considered by means of IEFPCM calculation with radii and non-electrostatic terms for Truhlar and co-workers’ SMD solvation model.\textsuperscript{[13]} The relevant structural parameters are collect in Table S1.

**Table S1:** Optimised B3LYP gas phase relevant distances (Å) for models A1, and B1. In parenthesis are shown the optimised distances in CHCl\textsubscript{3} using a Polarizable Continuum Model.

|       | A1    | B1   | (Model)     |
|-------|-------|------|-------------|
| C-I   | 2.138 | 2.122| (2.121)     |
| I⋯N   | 2.720 | 2.896| (3.061)     |

It is evident that the halogen bond distance increases slightly with the presence of larger substituents whereas the use of an implicit solvent model indicates that the C-I⋯N halogen bonds are \( \sim 3.0 \) Å long.

Taking this in consideration, we proceeded with the parameterization of the possible C-I⋯N halogen bond interactions present in 7·BF\textsubscript{4}. Parameterizations were performed with the addition of a specific term to the General Amber Force Field (GAFF)\textsuperscript{[14]} parameters used to describe the macrocycle components of the [2]catenane interlocked assembly as suggested in references \textsuperscript{[15]} and \textsuperscript{[16]}. The positive region on the electrostatic potential of the iodopyridinium moiety centred on the iodine atom is represented by a pseudo-atom (DU) with a van de Waals parameter set to zero, a C-I-DU bond angle set to 180º, and a bending force constant of 150 kcal mol\textsuperscript{-1} Å\textsuperscript{-2}. The optimal I-DU equilibrium distance was evaluated using several I-DU distances and computing the electrostatic potential and the Restricted Electrostatic Potential (RESP) charges for each new DU position. This was followed by a Molecular Mechanics (MM) minimization of the corresponding assembled catenane structures in Amber 12\textsuperscript{[17]}. 

S25
Subsequently, the MM optimised distances (I···N) were compared with the DFT data (Table 2). The electrostatic potential for the two individual macrocycles was calculated at the HF/6-31G* level, with the aug-cc-pVDZ-PP basis set for iodine using previously optimized B3LYP geometries at the theory level reported above for the model systems, and the atomic point charges for the individual macrocycles were determined according to the RESP methodology\cite{18} using a single conformation and Gaussian IOp (6/42=6) in agreement with the original GAFF reference.\cite{7} The MM optimized I···N and C-I distances are reported in Table S2 along with the relevant RESP charges.

**Table S2**: Gas phase MM optimised distances (Å) as a function of the I-DU distance together with the DU and iodine RESP charges.

| I-DU distance | C-I   | I···N  | DU charge | I charge   |
|---------------|-------|-------|-----------|------------|
| 2.00          | 2.091 | 3.118 | 0.108788  | -0.111542  |
| 2.10          | 2.092 | 3.062 | 0.097845  | -0.090483  |
| 2.20          | 2.093 | 2.963 | 0.088007  | -0.070660  |
| 2.35          | 2.164 | 2.600 | 0.074972  | -0.042888  |
| without DU    | 2.092 | ---   | ---       | 0.186479   |

**Figure S5**: MM minimized interlocked structures of 7* (top) with DU (I-DU distance 2.10 Å, left) and without DU (right) for the C-I···N halogen bond.
If a DU atom is not used, the halogen bond interactions are lost whereas the addition of the DU atom, independently of the distance, enables the description of the halogen bonds (see Figure S5). However, values of I-DU larger than 2.10 Å are not suitable since atom clashes occur during the subsequent MD simulations performed either in gas phase or in explicit CH₃Cl solution. The I-DU = 2.10 Å leading to an I⋯N distance of 3.062 Å, which compares well with the 3.061 Å value obtained for the DFT model B1 in CHCl₃ continuum solvent model, is the optimum value to describe I⋯N interactions and was selected for the further MD simulations reported in this work.

Moreover, preliminary gas phase MM calculations on the iodopyridinium macrocycle showed that default potential energy barrier (Vₚ) of 0.3 kcal for the X-ca-na-X torsion angle (where ca and na are the atom types assigned to the pyridinium ring carbon atoms and nitrogen atom, respectively, and X means any other atom type) led to a slight bending of the N-methyl group relatively to pyridinium ring plane. This structural imprecision was corrected using the torsion force field parameters available in the GAFF for the related X-cd-na-X torsion angle (4 / 6.8 / 180.0 / 2), where cd is a sp² carbon in non-pure aromatic systems.

**Generation of starting structures for the MD simulations.** Since there is no X-ray structure for catenane 7-BF₄ and given its conformational freedom, the starting structures for the MD simulations were generated by a protocol based on a gas-phase quenched dynamics simulation. The previous MM optimised structure with I-DU = 2.10 Å was subjected to a 5 ns MD run at 500 K saving a trajectory with 10000 structures that should sample most of the conformational space. All these structures were minimized by MM and clustered by RMSD similarity. Two structures corresponding to representative conformations of the most populated clusters were selected. These structures shown in Figure S6 as S1A and S1B present an C-I⋯N halogen bond and π–π donor-acceptor interactions between the
iodopyridinium and the hydroquinone rings of the macrocycle 1. These two co-conformations basically differ in the conformation adopted by the iodopyridinium macrocycle leading to slightly different binding scenarios.

**Figure S6**: Starting co-conformations used in the MD simulations, S1A and S1B exhibit an C-I⋯N halogen bond and S2A and S2B present an C-I⋯O halogen bond.

In order to increase the sampling, the iodopyridinium macrocycle in a structure similar to S1A was rotated affording an interlocked assembly with the C-I bond pointing away from the N of the pyridine ring. This structure was subjected to the same protocol mentioned earlier yielding two starting co-conformations S2A and S2B presented in Figure S6, where the C-I bond is pointing towards an oxygen atom from the polyether loop of the macrocycle 1.
**Molecular Dynamics Simulations.** The MM minimized conformations shown in Figures S6 were immersed in cubic box of CHCl$_3$ molecules$^{[20]}$ (~ 43 Å side, after equilibration). One BF$_4^{-}$ anion, with charges and parameters from reference$^{[21]}$, was used as counter-ion. All systems were simulated using the following multi-stage protocol. The solvent was initially relaxed keeping the solute fixed with a strong positional restraint (500 kcal mol$^{-1}$ Å$^{-2}$). Then, the restraint was removed and a MM energy minimisation of entire system was performed followed by a heating stage (0 to 300 K) during 50 ps using the Langevin thermostat with a collision frequency of 1 ps$^{-1}$ in an NVT ensemble and a weak positional restraint on the solute (10 kcal mol$^{-1}$ Å$^{-2}$). The system was then equilibrated for 5 ns in a NPT ensemble at 1 atm with isotropic pressure scaling using relaxation time of 2 ps and data collection was performed for 50 ns. All simulations were carried out with the pmemd.cuda AMBER executable, able to accelerate explicit solvent Particle Mesh Ewald (PME) calculations$^{[22]}$ through the use of GPUs.$^{[23]}$ All bonds involving hydrogen atoms were constrained using SHAKE$^{[24]}$ allowing the usage of 2 fs time step. A 10 Å cutoff was used for the non-bonded van der Waals interactions. Trajectory analysis was performed with the cpptraj utility of AmberTools12 while the molecular representations were drawn with PyMOL.$^{[25]}$ Plots were performed with Gnuplot.$^{[26]}$ Representative co-conformations from the MD trajectories in solution were obtained by clustering the structures by RMSD similarity, using the average-linkage clustering algorithm.$^{[27]}$ A frame from the most populated cluster was chosen as representative of the simulation.
MD simulations extended analysis.

**Figure S7:** Histograms for the distribution of the I···N distances (Å) and the C-I···N angles (º) for simulations with S1A and S1B. Data were collected during 50 ns.

**Figure S8:** Representative co-conformations of 7-BF₄ for simulations with S1A (left) and S1B (right).

**Extended discussion on simulations with S2A and S2B.** In the S2 scenarios (A and B), an C-I···O halogen bond is possible between the iodopyridinium and the three available oxygen atoms of the polyether loop numbered O1, O2, and O3 (see Figure S9). In these simulations we also monitored the distribution of the I···O distances and C-I···O angles and the results are plotted in Figure S9. It is clear that the results are very similar and independent of the starting co-conformation (A or B). Concerning the interaction with O1 or O3, the distances are too long and the angles are too low to be considered halogen bonds. For the C-I interaction with O2, the values are distributed around values more compatible with the presence of an halogen bond with average I···O distances and C-I···O angles of 3.60 Å and 164º for A and 3.51 Å and
164° for B co-conformations. However, contrary to what was found for simulations of C-I⋯N halogen bonds in S1A and S1B, the distributions of I⋯O distances for the simulations with S2A and S2B structures are very diffuse with respect to the C-I⋯O angle as evident when the corresponding histograms for this two type of halogen bonds are compared (Figure S7 versus Figure S9 middle. This is an indication that the possible C-I⋯O halogen bond is not sufficiently stable for halogen bond templation as it is the charged assisted I⋯N halogen bond.
Figure S9: Histograms for the distribution of the I···O distances (Å) and the C-I···O angles (º) for simulations with S2A and S2B. Data were collected along the 50 ns. The numbering scheme used for oxygen atoms is shown at the top.

Part V: References.

[1] K. M. Bonger, R. J. B. H. N. van den Berg, L. H. Heitman, A. P. Ijzerman, J. Oosterom, C. M. Timmers, H. S. Overkleeft, G. A. van der Marel, _Biorg. Med. Chem._ 2007, 15, 4841-4856.
[2] M. D. Lankshear, N. H. Evans, S. R. Bayly, P. D. Beer, _Chem. Eur. J._ 2007, 13, 3861-3870.
[3] S. Bhattacharya, K. Snehalatha, V. P. Kumar, _J. Org. Chem._ 2003, 68, 2741-2747.
[4] H. Takalo, P. Pasanen, J. Kankare, _Acta Chem. Scand., Ser. B_ 1988, 42, 373-377.
[5] P. Roquette, C. König, O. Hübner, A. Wagner, E. Kaifer, M. Enders, H.-J. Himmel, _Eur. J. Inorg. Chem._ 2010, 2010, 4770-4782.
[6] Crombie, L.; Ryan, A. P.; Whiting, D. A.; Yeboah, S. O. _J. Chem. Soc., Perkin Trans. 1_ 1987, 2783-2786.
[7] Choudhury, M. K. _J. Chem. Res., Synop_ 1995, 157.
[8] A. Caballero, F. Zapata, N. G. White, P. J. Costa, V. Félix, P. D. Beer, _Angew. Chem. Int. Ed._ 2012, 51, 1876-1880.
[9] F. Zapata, A. Caballero, N. G. White, T. D. W. Claridge, P. J. Costa, V. Félix, P. D. Beer, _J. Am. Chem. Soc._ 2012, 134, 11533-11541.
[10] Gaussian 09, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, J. J. A. Montgomery, T. Vreven, K. N. Kudin, J. C. Burant, J. M. Millam, S. S. Izmaylov, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G. A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J. E. Knox, H. P. Hratchian, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, P. Y. Ayala, K. Morokuma, G. A. Voth, P. Salvador, J. J. Dannenberg, V. G. Zakrzewski, S. Dapprich, A. D. Daniels, M. C. Strain, O. Farkas, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. V. Ortiz, Q. Cui, A. G. Baboul, S. Clifford, J. Cioslowski, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, C. Gonzalez, J. A. Pople, Gaussian, Inc., Wallingford CT, 2009.
[11] a) A. D. Becke, _J. Chem. Phys._ 1993, 98, 5648-5652; b) C. Lee, W. Yang, R. G. Parr, _Phys. Rev. B_ 1988, 37, 785-789.
[12] K. L. Schuchartd, B. T. Didier, T. Elsethagen, L. Sun, V. Gurumoorthi, J. Chase, J. Li, T. L. Windus, _J. Chem. Inf. Model._ 2007, 47, 1045-1052.
[13] A. V. Marenich, C. J. Cramer, D. G. Truhlar, _J. Phys. Chem._ B 2009, 113, 6378-6396.
[14] J. Wang, M. R. Wolf, J. W. Caldwell, P. A. Kollman, D. A. Case, _J. Comput. Chem._ 2004, 25, 1157.
[15] M. A. A. Ibrahim, _J. Comput. Chem._ 2011, 32, 2564-2574.
[16] S. Rendine, S. Pieraccini, A. Forni, M. Sironi, _Phys. Chem. Chem. Phys._ 2011, 13, 19508–19516.
[17] D. A. Case, T. A. Darden, T. E. Cheatham, III, C. L. Simmerling, J. Wang, R. E. Duke, R. Luo, R. C. Walker, W. Zhang, K. M. Merz, B. Roberts, S. Hayik, A. Roitberg, G. Seabra, J. Swails, A. W. Götz, I. Kolossváry, K. F. Wong, F. Rueda, J. Vanicek, R. M. Wolf, J. Liu, X. Wu, S. R. Brozell, T. Steinbrecher, H. Gohlke, Q. Cai, X. Ye, J. Wang, M.-J. Hsieh, G. Cui, D. R. Roe, D. H. Mathews, M. G. Seetin, R. Salomon...
Ferrer, C. Sagui, V. Babin, T. Luchko, S. Gusarov, A. Kovalenko, P. A. Kollman, AMBER 12, University of California, San Francisco, 2012.

[18] C. I. Bayly, P. Cieplak, W. Cornell, P. A. Kollman, J. Phys. Chem. 1993, 97, 10269-10280.

[19] A. Rappe, C. Casewit, “Molecular Mechanics Across Chemistry”, University Science Books, Sausalito, CA, 1997.

[20] P. Cieplak, J. Caldwell, P. Kollman, J. Comput. Chem., 2001, 22, 1048–1057.

[21] X. Wu, Z. Liu, S. Huang, W. Wang, Phys. Chem. Chem. Phys. 2005, 7, 2771-2779.

[22] a) T. Darden, D. York, L. Pedersen, J. Chem. Phys. 1993, 98, 10089–10092; b) U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee, L. G. Pedersen, J. Chem. Phys. 1995, 103, 8577–8593.

[23] a) see http://ambermd.org/gpus/ (accessed in 2012/10/10). b) A. W. Goetz, R. Salomon-Ferrer, D. Poole, S. L. Grand, R. C. Walker, "Routine microsecond molecular dynamics simulations with AMBER - Part II: Particle Mesh Ewald" (in preparation), 2011.

[24] J.-P. Ryckaert, G. Ciccotti, H. J. C. Berendsen, J. Comput. Phys. 1977, 23, 327–341.

[25] PyMOL Molecular Graphics System, Version 1.2r2, DeLano Scientific LLC, 2009.

[26] T. Williams, C. Kelley, Gnuplot 4.4: An Interactive Plotting Program, 2010. URL: http://www.gnuplot.info

[27] J. Shao, S. W. Tanner, N. Thompson, T. E. Cheatham III, J. Chem. Theory Comput. 2007, 3, 2312–2334.